Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATURE: Trastuzumab emtansine in HER2-equivocal breast cancer
NCT02725541Phase 2Withdrawn
- Start
- Mar 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer. Planned start Mar 2016; status: withdrawn.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02725541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725541.